Patents
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
11/2010
11/10/2010CN101005831B Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
11/09/2010US7831310 Microprocessor controlled ambulatory medical apparatus with hand held communication device
11/09/2010US7829694 surgerical insertion of catheter; supplying protein antagonistl Alzheimer's disease; Parkinson's disease; Huntington's disease; Spinocerebella atropy
11/09/2010US7829693 Compositions and methods for inhibiting expression of a target gene
11/09/2010US7829616 anhydrous; polyethylene glycol; ethylene oxide-propylene oxide copolymer; biocompatible; handling characteristics (hardness, ductility, malleability) that range from a grease to a wax for medical and surgical applications; bone hemostat; implant; adhesive; thermoreversible hydrogel drug delivery
11/09/2010US7829595 A mixture of compound, e.g., cinacalcet hydrochloride and excipient in dosage form having a controlled dissolution profile , which comprises 50-125% of a target amount of theactive compound is released in 0.05 hydrochloric acid in 30 minutes; calcimimetics and calcilytics; hyperparathyroidism
11/09/2010US7829544 Aqueous solution preparation containing aminoglycoside antibiotic and bromfenac
11/09/2010US7829533 Cyclosporin analog formulations
11/09/2010US7829525 a surface active substance, in particular a non-ionic detergent (tenside), and a mixture of at least two amino acids, are either Glu and Gln or Asp and Asn for stabilization of protein agents in pharmaceuticals
11/09/2010US7829518 Aqueous solution of olanexidine, method of preparing the aqueous solution, and disinfectant
11/09/2010US7829499 Time-release agent comprising an aqueous solution of both nondisintegrating acid pesticide granules and a water soluble pesticide; a cationic surfactant and base; sulfonylureas and difluoromethanesulfonylanilide dissolve after 30 minutes; environmentally friendly; nonphytotoxic; simplification
11/09/2010US7829124 administering an effective amount of an aqueous or alcohol extract of Phyllanthus to a mammal infected with the YMDD hepatitis B virus mutant strain resistant; inhibiting viral gene expression in a mammal infected with a hepatitis B virus
11/09/2010US7829123 Process
11/09/2010US7829122 Microgranules based on active principle and method for making same
11/09/2010US7829121 once-daily oral administration; FDA Orange book listed patent for cyclobenzaprine hydrochloride
11/09/2010US7829120 once a day oral administration formulation contains trazodone or salt, phosphorus oxychloride cross-linked high amylose starch, hydroxypropylmethylcellulose, sodium stearyl fumarate, colloidal silica, optional cetylpyridinium chloride and alganic acid; antidepressant; sleep disorder; sustained release
11/09/2010US7829119 Hollow nanoparticles; self-assembly; polyelectrolyte eg polyamine
11/09/2010US7829118 crosslinked hydrogel particles in solution of hyaluronic acid in saline, where particles are formed by reaction of polyethylene glycol dithiol with hyaluronic acid having 1-10% of its hydroxyl groups derivatized with 2-(vinylsulfonyl)ethoxy groups; use in medical devices, biomedical adhesives, sealants
11/09/2010US7829116 Adhesive-forming composition and blend of adhesives obtained therefrom
11/09/2010US7829115 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
11/09/2010US7829114 Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
11/09/2010US7829113 comprising one or more phosphatidylcholines, an N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, an encapsulated drug, cholesterol; cancer treatment
11/09/2010US7829112 Forming two drug permeable polymeric segments, exposing to preferential drug, connecting segments, delivering drug treatment; for use in treatment of menopausal symptoms and benign ovarian secretory disorder; contraceptive
11/09/2010US7829110 increasing tear resistance of scar tissue during wound repair by applying to a wound a surgical mesh comprising an anabolic steroid and a corticosteroid disposed in or on a surgical mesh structure
11/09/2010US7829109 Catheter injectable depot compositions and uses thereof
11/09/2010US7829108 producing a bioscaffold by decellularizing a tissue to produce a bioscaffold having pores therein; decellularizing the tissue with an oxidant and detergent simultaneously to remove extraneous material and increase the pore size and porosity therein, wherein at least 70% of cells are removed from tissue
11/09/2010US7829107 drug delivery; skin disorders; supplying corticosteroid and fungicides
11/09/2010US7829106 comprises a polyglycerol fatty acid ester obtained from a polyglycerol having a hydroxyl value of 1200 or less and primary hydroxyl groups in an amount of 50% or more and 70.5% or less of the total hydroxyl groups and one or more kinds of fatty acids having 8 to 22 carbon atoms; high viscosity
11/09/2010US7829105 bioactive glass particles capable of inducing bone growth individually microencapsulated with a coating comprising a biodegradable polymer; the mass ratio of bioactive particles to coating ranges from 1:2-10:1; dry, granular composition when wetted forms a syringeable paste capable of repairing bone
11/09/2010US7829099 comprises from 2% to 55% by weight of at least one polymer which forms a gel in water, water, from 0.1% to 15% by weight of a sea algae extract, and from 1% to 85% by weight of alcohol selected from monohydric and polyhydric alcohols, each based on a total weight of the matrix; drug delivery
11/09/2010US7829098 Herbal powder extracts and methods of preparing and using the same
11/09/2010US7829080 stably retaining reduced coenzyme Q10 by protection against oxidation while maintaining high safety, during processing; useful as a food, nutritional product, nutritional supplement, animal drug, drink, feed, cosmetic, pharmaceutical product; dosage form
11/09/2010US7829074 Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG
11/09/2010US7829068 0.1 to 4.5 wt. % dihydroxyacetone (DHA) incorporated in lamellae resulting from a mixture of phospholipids, lipids, organic solvents, water and DHA and prepared by a high-pressure homogenization process, 0.15 to 3.5 wt. % free dihydroxyacetone, phospholipids. alcoholic extracts from orange peel, tulips
11/09/2010US7829064 antigen binding molecules conjugated to lipids, polymer carriers, micelles, nanoparticles or mixtures and effectors, used for therapy of diagnosis
11/09/2010US7828792 MRI compatible programmable valve pump
11/09/2010US7828772 Fluid dispensing device
11/09/2010US7828711 Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
11/09/2010US7827986 Methods for treating jaw pain
11/09/2010US7827982 Biodrug delivery via thermal inkjet method for transmucosal delivery; peptides and proteins such as insulin, growth hormone, antibodies, interferons, cytokines
11/09/2010CA2624110C A rapidly-dissolving orally administrable wafer formulation
11/09/2010CA2499882C Modified release dosage form with two cores
11/09/2010CA2458209C Compositions comprising pectin and ascorbic acid
11/09/2010CA2441609C Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof
11/09/2010CA2438544C Aerosol compositions containing formoterol for delivery to the lungs via nebulization
11/09/2010CA2430828C Pharmaceutical preparation comprising an active dispersed on a matrix
11/09/2010CA2421685C Soft tablet containing high molecular weight polyethylene oxide
11/09/2010CA2420038C Devices for intraocular drug delivery
11/09/2010CA2405190C Simethicone solid oral dosage form
11/09/2010CA2391983C Controlled-release dosage forms comprising zolpidem or a salt thereof
11/04/2010WO2010127345A2 Orally disintegrating tablet compositions comprising combinations of high and low-dose drugs
11/04/2010WO2010127254A2 Thermoresponsive, biodegradable, elastomeric material and uses therefor
11/04/2010WO2010127206A2 Intraocular bioactive agent delivery compositon including a molecular partitioning system
11/04/2010WO2010127205A2 Fixed dose drug combination formulations
11/04/2010WO2010127198A1 Formulation for oral administration of apoptosis promoter
11/04/2010WO2010127193A1 Stabilized lipid formulation of apoptosis promoter
11/04/2010WO2010127192A1 Lipid formulation of apoptosis promoter
11/04/2010WO2010127191A1 Solid oral formulation of abt-263
11/04/2010WO2010127159A2 Polymeric micelles for polynucleotide encapsulation
11/04/2010WO2010127154A1 Polymers for polynucleotide encapsulation
11/04/2010WO2010127125A1 Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
11/04/2010WO2010127033A1 Formulations of cannabidiol and methods of using the same
11/04/2010WO2010126911A1 Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
11/04/2010WO2010126909A1 Formulation of tocotrienol quinones for the treatment of ophthalmic diseases
11/04/2010WO2010126908A1 Compositions and methods for treating insulin resistance and diabetes mellitus
11/04/2010WO2010126828A1 Co-processed excipient compositions
11/04/2010WO2010126818A1 Intranasal delivery system for dantrolene
11/04/2010WO2010126676A1 Oral formulations of bendamustine
11/04/2010WO2010126501A1 Cannabinoid-containing compositions and methods for their use
11/04/2010WO2010126168A2 Solid preparation
11/04/2010WO2010126124A1 Transdermal preparation
11/04/2010WO2010125691A1 Adhesive patch
11/04/2010WO2010125541A1 A pharmaceutical, dermatological, nutritional or cosmetic composition for combating the immunosuppressive action of aggressive agents on the skin
11/04/2010WO2010125516A1 Compositions containing a mixture of lutein and zeaxanthine and coated with chocolate
11/04/2010WO2010125475A2 Sustained release formulations
11/04/2010WO2010125470A2 Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
11/04/2010WO2010125468A1 Composition for the treatment of prostate cancer
11/04/2010WO2010125408A2 Prostata-norm rectal suppositories for the treatment of prostatitis
11/04/2010WO2010125313A1 Compressible and free-flow co-agglomerates of mannitol and granular starch
11/04/2010WO2010125271A1 Use of n2o gas for treating chronic pain
11/04/2010WO2010125143A1 Use of allopurinol for the treatment of hand foot skin reaction
11/04/2010WO2010125087A1 Process to form an orally disintegrating tablet for human use
11/04/2010WO2010125084A1 Process to form a tablet and apparatus suitable for applying this process
11/04/2010WO2010124837A2 Encapsulated liver cell composition
11/04/2010WO2010124655A1 Complex microcapsule comprising epiphyseal plate chondrocytes and preparation method and use thereof
11/04/2010WO2010124654A1 Vascular embolus of sodium alginate microspheres comprising drug for resisting hemangioma, preparation method, and use thereof
11/04/2010WO2010124623A1 Medicine for preventing and treating alzheimer's disease and preparative method thereof
11/04/2010WO2010124601A1 Method for producing injectable preparation containing ceftriaxone sodium and tazobactam sodium
11/04/2010WO2010124540A1 Flexible liposome of resveratrol and preparation method thereof
11/04/2010WO2010124525A1 Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
11/04/2010WO2010124520A1 Pharmaceutical composition for treating abnormal energy metabolism and use thereof
11/04/2010WO2010124428A1 A stabilizer for preparing freeze-dried vaccine without gelatin and the preparation method of freeze-dried vaccine
11/04/2010WO2010124387A1 Bacterial compositions for prophylaxis and treatment of degenerative disease
11/04/2010WO2010101628A3 Methods and products for in vivo enzyme profiling
11/04/2010WO2010101485A3 A pharmaceutical composition containing celecoxib and a process of the manufacture thereof
11/04/2010WO2010089768A3 Bortezumib containing pharmaceutical composition
11/04/2010WO2010085696A3 Sustained released delivery of one or more agents
11/04/2010WO2010083035A3 Transdermal administration of tamsulosin
11/04/2010WO2010082219A3 An arteether injection for treatment of malaria
11/04/2010WO2010081032A3 Steroidal compositions